Clinical trials: Stage IV
Non-small Cell Lung Cancer Metastatic
Predictive Multimodal Signatures Associated With Response to Treatment and Prognosis of Patients With Stage IV Non-small Cell Lung Cancer
Predicting response to therapy and disease progression in stage IV NSCLC patients treated with pembrolizumab monotherapy, chemotherapy-pembrolizumab combination therapy or chemotherapy alone in the first-line setting.
- Trial name
- DEEP-Lung-IV (NCT04994795)
- Testing
- Predictive models (data collection)
- Where
- 30 sites in United States, Brazil and 6 more
- Volunteers
- 4,000 people
- Sponsor
- Sophia Genetics SAS
NSCLC Stage IV
AB-16B5 Combined With Docetaxel in Subjects With Metastatic Non-Small Cell Lung Cancer (EGIA-002)
This Phase II study will recruit 40 metastatic non-small cell lung cancer patients who failed treatment with a platinum-containing doublet treatment and an anti-PD1 or PD-L1 immune checkpoint antibody, administered simultaneously…
- Trial name
- NCT04364620
- Testing
- AB-16B5, Docetaxel
- Where
- 5 sites in United States, Canada
- Volunteers
- 35 people
- Sponsor
- Alethia Biotherapeutics
NSCLC Stage IV
Study of AGEN1884 With Pembrolizumab in 1L NSCLC
A Phase IIa Open-Label Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of AGEN1884 in Combination with Pembrolizumab in Subjects with Chemotherapy Naïve, PD-L1 high, metastatic…
- Trial name
- NCT03411473
- Testing
- AGEN1884 in combination with pembrolizumab
- Where
- 5 sites in Australia, New Zealand
- Volunteers
- 2 people
- Sponsor
- Agenus Inc.
Pancreatic Cancer
Safety and Efficacy of G17DT Immunogen Combined With Gemcitabine vs. Gemcitabine in the Treatment of Advanced Pancreatic Carcinoma
This study will test whether the G17DT Immunogen, when administered in combination with chemotherapy, is an effective and safe treatment for pancreatic cancer.
- Trial name
- NCT00044031
- Testing
- G17DT Immunogen
- Volunteers
- 394 people
- Sponsor
- Cancer Advances Inc.
Healthy Subjects
Trial to Evaluate the PK Profile of Glepaglutide (ZP1848) After a Single IV and After Multiple SC Injections in Healthy Subjects
The primary objective of the trial is to characterize the pharmacokinetic (PK) profiles of glepaglutide and its primary active metabolites following once-daily and once-weekly subcutaneous (SC) injections and after a single…
- Trial name
- NCT03279302
- Testing
- Glepaglutide
- Where
- United States
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Zealand Pharma
Stage IV Pancreatic Cancer
Study of Gemcitabine + PEGPH20 vs Gemcitabine Alone in Stage IV Previously Untreated Pancreatic Cancer
Phase 1B: Open label (all patients receive PEGPH20+gemcitabine), dose escalation, safety and tolerability study to determine the safe dose of PEGPH20 to use in combination with gemcitabine in Stage IV previously untreated…
- Trial name
- NCT01453153
- Testing
- Gemcitabine, PEGPH20
- Where
- 12 sites in United States, Russia
- Volunteers
- 28 people
- Sponsor
- Halozyme Therapeutics
Peripheral Neuropathic Pain
Observation of the Use of QUTENZA™ in Standard Clinical Practice
This non-interventional study will evaluate the efficacy, tolerability, health related quality of life and use of health resources associated with QUTENZA treatment when QUTENZA is used in standard clinical practice.
- Trial name
- ASCEND (NCT01737294)
- Testing
- Qutenza exposure
- Where
- 50 sites in Austria, Greece and 5 more
- Volunteers
- 429 people
- Sponsor
- Astellas Pharma Europe Ltd.
Glabellar Frown Lines
Long-term Open-label Treatment of Moderate to Severe Glabellar Lines With CORETOX®
This study evaluates the long-term safety and efficacy of CORETOX in the treatment of moderate to severe glabellar lines.
- Trial name
- NCT04281745
- Testing
- CORETOX Inj
- Where
- South Korea
- Volunteers
- 200 people
- Sponsor
- Medy-Tox
Stage IV Melanoma
A Study of Volociximab in Metastatic Melanoma
This is a Phase 2, multicenter, research study determining the effects of an investigational drug called volociximab in metastatic melanoma. The purpose of the study is to compare the clinical benefit and safety of volociximab.
- Trial name
- NCT00369395
- Testing
- volociximab
- Where
- 7 sites in United States
- Volunteers
- 19 people
- Sponsor
- Abbott
Prevention of Atherothrombotic Events, Coronary Artery Disease (CAD)
Study to Learn More About the Safety and Effectiveness of Rivaroxaban (Xarelto) When Given Together With Acetylsalicylic Acid to Indian People With Narrowing of the Arteries of the Heart (CAD) and/or With Reduced Blood Flow in the Arteries of the Legs and Arms With Symptoms (Symptomatic PAD)
This is an observational study in which data from Indian people with coronary artery disease and / or symptomatic peripheral artery disease who will be receiving the drug rivaroxaban (Xarelto) are studied.
- Conditions
- Prevention of Atherothrombotic Events, Coronary Artery Disease (CAD), Symptomatic Peripheral Artery Disease (Symptomatic PAD)
- Trial name
- NCT04298567
- Testing
- Rivaroxaban (Xarelto,Bay 59-7939), Acetylsalicylic acid(ASA)
- Where
- India
- Volunteers
- 300 people
- Sponsor
- Bayer
Restless Legs Syndrome
A Phase IV Trial With Pramipexole to Investigate the Effects on RLS Symptoms and Sleep Disturbance in Patients With RLS
The primary objective of this study is to investigate the effects on RLS symptoms and sleep disturbance of pramipexole (Mirapexin) 0.125 mg/day to 0.75 mg/day per os for 12 weeks, compared to placebo, in the treatment of patients…
- Trial name
- NCT00349531
- Testing
- Pramipexole
- Where
- 49 sites in Denmark, Finland and 7 more
- Volunteers
- 369 people
- Sponsor
- Boehringer Ingelheim
Kidney Transplant
Observational Registry Study of Renal Transplant Patients
The MORE Observational Study follows real-world renal transplant patients with the data resolution of a monitored, prospective clinical trial for 5 years.
- Trial name
- MORE registry (NCT01284257)
- Where
- 8 sites in United States
- Sponsor
- Novartis Pharmaceuticals
Advanced Clear Cell Renal Cell Carcinoma, Advanced Renal Cell Carcinoma
CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer
This phase I trial tests the safety, side effects, best dose, and effectiveness of CBM588 in combination with nivolumab and ipilimumab in treating patients with kidney cancer that may have spread from where it first started to…
- Conditions
- Advanced Clear Cell Renal Cell Carcinoma, Advanced Renal Cell Carcinoma, Advanced Sarcomatoid Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma
- Trial name
- NCT06399419
- Testing
- Biospecimen Collection, Bone Scan, CBM588 Capsules
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Osel, Inc.
Diabetes Mellitus, Type 2
Glibenclamide (Dose to be Titrated From Starting Dose of 5mg om) Plus Rosiglitazone 4mg om (Increased to 8mg om After 6 Months) and vs Glibenclamide (Dose to be Titrated With Starting Dose of 5mg om) Plus Placebo, Administered to Patients With Type 2 Diabetes Mellitus
Rationale Rosiglitazone and troglitazone both promote differentiation of pre-adipocytes into adipocytes in subcutaneous, but not omental fat, and reduce gamma glutamyl transferase, a surrogate marker for intra-abdominal and…
- Trial name
- NCT01045590
- Testing
- titration
- Where
- 4 sites in South Korea
- Volunteers
- 100 people
- Sponsor
- GlaxoSmithKline
Secondary Hyperparathyroidism
A Study to Assess the Efficacy and Safety of Paricalcitol in the Treatment of Chronic Kidney Disease With Secondary Hyperparathyroidism
The study is being conducted to evaluate the efficacy, and safety of Paricalcitol for secondary hyperparathyroidism with stage 3 and stage 4 chronic kidney disease in adults.
- Trial name
- NCT04994080
- Testing
- Paricalcitol
- Volunteers
- 84 people
- Sponsor
- Chengdu Suncadia Medicine Co., Ltd.
Mild Cognitive Impairment
Evaluation the Effect of Acetyl-L-carnitine in Patients With Mild Cognitive Impairment Accompanied With Chronic Cerebrovascular Disease
The purpose of this study is to evaluate the efficacy of Acetyl-L-carnitine in patient with Mild Cognitive Impairment associated with chronic cerebrovascular disease.
- Trial name
- NCT04346862
- Testing
- Acetyl-L-carnitine hydrochloride 500mg
- Where
- South Korea
- Volunteers
- 636 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Renal Insufficiency, Chronic, Diabetes Mellitus, Type 2
A Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Effects of Bardoxolone Methyl on Body Composition in Patients With Stage 4 Chronic Kidney Disease and Type 2 Diabetes Mellitus
This multicenter, randomized, double-blind, placebo-controlled Phase 2 safety study will assess the effect of bardoxolone methyl relative to placebo on body weight and fat mass in approximately 60 patients with stage 4 Chronic…
- Trial name
- NCT01655186
- Testing
- Bardoxolone Methyl
- Sponsor
- Biogen
Asthma
Phase IV Study in Asthma Subjects for Dry Powder Inhaler (DPI) Versus (vs) Metered Dose Inhaler (MDI) Correct Use
The study is conducted to evaluate the potentially improved patient handling of the ELLIPTA Dry Powder Inhaler (DPI). Therefore, the study aims to evaluate errors encountered by subject with asthma during handling ELLIPTA DPI…
- Trial name
- NCT02794480
- Testing
- ELLIPTA DPI, GSK MDI, AZ MDI
- Where
- 20 sites in United States
- Volunteers
- 324 people
- Sponsor
- GlaxoSmithKline
Kidney Cancer
Interleukin-2, Vinblastine, and GM-CSF in Treating Patients With Metastatic Kidney Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Interleukin-2 may stimulate a person's white blood cells to kill cancer cells.
- Trial name
- NCT00003181
- Testing
- aldesleukin, sargramostim, vinblastine sulfate
- Where
- 2 sites in United States
- Volunteers
- 35 people
- Sponsor
- Hope Cancer Institute, Inc.
Healthy
Bioequivalence Study of Tramadol Hydrochloride /Paracetamol Tablets Versus Ultracet Tablets
The sponsor, Pfizer has developed a formulation of tramadol hydrochloride/ paracetamol 37.5 mg/ 325 mg (test drug) as a generic alternative to the reference listed product Ultracet®.
- Trial name
- NCT03803371
- Testing
- Ultracet Tablets, Tramadol hydrochloride 37.5 mg/Paracetamol 325 mg tablets - tablet (Pfizer)
- Where
- Brazil
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Pfizer